Eagle Pharmaceuticals Retained Earnings (Accumulated Deficit) 2013-2023 | EGRX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Eagle Pharmaceuticals retained earnings (accumulated deficit) from 2013 to 2023. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Eagle Pharmaceuticals Retained Earnings (Accumulated Deficit) 2013-2023 | EGRX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$196.7B
Stryker (SYK)	$142.8B
Boston Scientific (BSX)	$132.8B
EssilorLuxottica (ESLOY)	$110.9B
Medtronic (MDT)	$105.8B
Haleon (HLN)	$44.2B
Lonza Group Ag (LZAGY)	$43.1B
GE HealthCare Technologies (GEHC)	$37.1B
ResMed (RMD)	$35B
Terumo (TRUMY)	$29.6B
Koninklijke Philips (PHG)	$24.2B
Zimmer Biomet Holdings (ZBH)	$21.2B
Insulet (PODD)	$18.9B
Baxter (BAX)	$15.5B
Smith & Nephew SNATS (SNN)	$11.2B
BellRing Brands (BRBR)	$10B
Bio-Rad Laboratories (BIO)	$9.4B
Demant (WILYY)	$8.3B
Lantheus Holdings (LNTH)	$6.5B
Haemonetics (HAE)	$4.1B
Prestige Consumer Healthcare (PBH)	$4.1B
ICU Medical (ICUI)	$4B
Perrigo (PRGO)	$3.7B
Envista Holdings (NVST)	$3.4B
Shandong Weigao Medical Polymer (SHWGF)	$3B
GN Store Nord (GNNDY)	$2.9B
QuidelOrtho (QDEL)	$2.8B
Neogen (NEOG)	$2.6B
LeMaitre Vascular (LMAT)	$2.3B
Green Thumb Industries (GTBIF)	$1.7B